Wasmuth Jan-Christian, Nischalke Hans-Dieter, Jütte Alexander, Fätkenheuer Gerd, Salzberger Bernd, Sauerbruch Tilman, Spengler Ulrich, Rockstroh Jürgen K, Dumoulin Franz L
Department of Medicine I, University of Bonn, Sigmund Freud Str. 25, 53105 Bonn, Germany.
Antiviral Res. 2004 Mar;61(3):207-12. doi: 10.1016/j.antiviral.2003.11.003.
To compare CC chemokine mRNA levels from native peripheral blood mononucleated cells (PBMCs) before and 6 months after the initiation of two different regimens of highly active antiretroviral therapy (HAART), we treated group 1 (n = 11) with two nucleoside analogues and the protease inhibitor (PI) indinavir boosted by ritonavir (800/100 mg b.i.d.); group 2 (n = 8) was treated with the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz instead of PI. CC chemokine mRNA levels (regulated upon T cell activation expressed secreted [RANTES], macrophage inhibitory protein [MIP]-1alpha, MIP-1beta, monocyte chemotactic protein [MCP]-1, MCP-2) were quantified from PBMCs before and 6 months after the initiation of HAART using a reverse transcription/real-time polymerase chain reaction (PCR) assay. The mRNA levels of MCP-1 and MCP-2 were significantly decreased in both groups (P < 0.05), while MIP-1alpha and MIP-1beta were decreased significantly only in the PI-treated group, but not in the NNRTI group. A moderate decrease of RANTES was observed in both treatment groups. The data suggest that HAART regimens containing either NNRTI or PI are not equivalent with regard to modification of CC chemokine mRNA profiles.
为比较两种不同高效抗逆转录病毒疗法（HAART）方案启动前及启动6个月后天然外周血单个核细胞（PBMC）中CC趋化因子mRNA水平，我们对第1组（n = 11）采用两种核苷类似物及由利托那韦增强的蛋白酶抑制剂（PI）茚地那韦（800/100 mg，每日2次）进行治疗；第2组（n = 8）采用非核苷类逆转录酶抑制剂（NNRTI）依非韦伦替代PI进行治疗。使用逆转录/实时聚合酶链反应（PCR）分析法对HAART启动前及启动6个月后的PBMC中CC趋化因子mRNA水平（T细胞活化时调控表达分泌的[RANTES]、巨噬细胞炎性蛋白[MIP]-1α、MIP-1β、单核细胞趋化蛋白[MCP]-1、MCP-2）进行定量。两组中MCP-1和MCP-2的mRNA水平均显著降低（P < 0.05），而MIP-1α和MIP-1β仅在PI治疗组中显著降低，在NNRTI组中未降低。两个治疗组均观察到RANTES有中度降低。数据表明，含NNRTI或PI的HAART方案在改变CC趋化因子mRNA谱方面并不等效。
Zotero 插件